Amitivir

Amitivir (LY 217896), a thiadiazole derivative, possesses broad antiviral activity against orthomyxo- and paramyxoviruses. Amitivir is effective against influenza A and B viruses.

The mean 50% inhibitory concentration of Amitivir inhibits six strains of type A influenza (A/Russia, A/Brazil/11/78, A/Ann Arbor/1/57, A/Port Chalmers/1/73, A/Hong Kong/8/68 and A/X-15) ranged from 0.37 to 1.19 μg/ml. The mean 50% inhibitory concentration of Amitivir inhibits four strains of influenza B virus (B/Maryland/11/59, B/GreatLakes/1739/54, B/Singapore/3/64, B/Lee/40) ranged from 0.75 to 1.54 μg/ml^[2].

Amitivir (LY 217896) (9 mg/m² of body surface area per day) administered in the diet, in the drinking water, by oral gavage, by intraperitoneal injection, or by aerosolization was well tolerated and protected CD-1 mice infected with a lethal dose of influenza A or B virus^[2].

References:
[1]. Hayden FG, et al. Oral LY217896 for prevention of experimental influenza A virus infection and illness in humans. Antimicrob Agents Chemother. 1994;38(5):1178-1181.
[2]. Colacino JM, et al. Evaluation of the anti-influenza virus activities of 1,3,4-thiadiazol-2-ylcyanamide (LY217896) and its sodium salt. Antimicrob Agents Chemother. 1990;34(11):2156-2163.